Scholarlink

<p>Nanostructured lipid carriers (NLCs) are the latest advancement in formulations and more rational drug delivery systems, addressing several drawbacks associated with the use of micro-sized formulations. Such advancements include the creation of second-generation nanoparticles and their inherent ability to overcome the factors limiting solid lipid nanoparticles, such as inefficiencies in drug entrapment and stability. NLC a non-stoichiometric lipid composition refers to the mixture of solid and liquid lipids, where the ratio of these lipids is not fixed or predetermined. The physical and chemical properties of NLCs are rigorously examined in this review, with a focus on the NLCs’ strategic significance in combating drug resistance, biocompatibility, and multifunctional potential. To address important issues with drug delivery and therapeutic efficacy, particular attention is paid to how NLCs improve drug solubility and provide selective targeting. Suppose performance across application domains includes cancer treatment, organ targeting, and post-primary wound healing, In that case, such NLCs look promising, but know how to make hydrophobic drugs and phytochemicals more soluble in the first place. The market for lipid nanoparticles is expected to develop at a compound annual growth rate (CAGR) of 13.6% between 2022 and 2029, according to the analysis. This indicates that the demand for lipid based delivery systems is rising globally and that the range of applications for these systems is expanding. To improve their therapeutic efficacy and safety profile, the paper also explores current developments in NLC technology, such as surface changes intended to allow controlled drug release and reduce cytotoxicity. NLCs present a viable platform for next-generation drug delivery by tackling important issues such as systemic toxicity, restricted solubility, extensive first-pass metabolism, and poor oral bioavailability. They are positioned as a crucial innovation in the future of precision medicine due to their capacity to improve patient outcomes and increase therapeutic efficacy.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Next-Generation Nanostructured Lipid Carriers: A Review of Latest Trends and Innovations

  • 期刊论文

  • 发表日期：

    2025年12月4日

查看全文
  • Chandan Nayak,
  • Ranjit Prasad Swain,
  • Rajaram Mohapatra,
  • Kahnu Charan Panigrahi

摘要

Nanostructured lipid carriers (NLCs) are the latest advancement in formulations and more rational drug delivery systems, addressing several drawbacks associated with the use of micro-sized formulations. Such advancements include the creation of second-generation nanoparticles and their inherent ability to overcome the factors limiting solid lipid nanoparticles, such as inefficiencies in drug entrapment and stability. NLC a non-stoichiometric lipid composition refers to the mixture of solid and liquid lipids, where the ratio of these lipids is not fixed or predetermined. The physical and chemical properties of NLCs are rigorously examined in this review, with a focus on the NLCs’ strategic significance in combating drug resistance, biocompatibility, and multifunctional potential. To address important issues with drug delivery and therapeutic efficacy, particular attention is paid to how NLCs improve drug solubility and provide selective targeting. Suppose performance across application domains includes cancer treatment, organ targeting, and post-primary wound healing, In that case, such NLCs look promising, but know how to make hydrophobic drugs and phytochemicals more soluble in the first place. The market for lipid nanoparticles is expected to develop at a compound annual growth rate (CAGR) of 13.6% between 2022 and 2029, according to the analysis. This indicates that the demand for lipid based delivery systems is rising globally and that the range of applications for these systems is expanding. To improve their therapeutic efficacy and safety profile, the paper also explores current developments in NLC technology, such as surface changes intended to allow controlled drug release and reduce cytotoxicity. NLCs present a viable platform for next-generation drug delivery by tackling important issues such as systemic toxicity, restricted solubility, extensive first-pass metabolism, and poor oral bioavailability. They are positioned as a crucial innovation in the future of precision medicine due to their capacity to improve patient outcomes and increase therapeutic efficacy.

Graphical Abstract